These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 17565157)

  • 21. Cancer risk of heterozygotes with the NBN founder mutation.
    Seemanová E; Jarolim P; Seeman P; Varon R; Digweed M; Swift M; Sperling K
    J Natl Cancer Inst; 2007 Dec; 99(24):1875-80. PubMed ID: 18073374
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The BARD1 Cys557Ser variant and breast cancer risk in Iceland.
    Stacey SN; Sulem P; Johannsson OT; Helgason A; Gudmundsson J; Kostic JP; Kristjansson K; Jonsdottir T; Sigurdsson H; Hrafnkelsson J; Johannsson J; Sveinsson T; Myrdal G; Grimsson HN; Bergthorsson JT; Amundadottir LT; Gulcher JR; Thorsteinsdottir U; Kong A; Stefansson K
    PLoS Med; 2006 Jul; 3(7):e217. PubMed ID: 16768547
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The average cumulative risks of breast and ovarian cancer for carriers of mutations in BRCA1 and BRCA2 attending genetic counseling units in Spain.
    Milne RL; Osorio A; Cajal TR; Vega A; Llort G; de la Hoya M; Díez O; Alonso MC; Lazaro C; Blanco I; Sánchez-de-Abajo A; Caldés T; Blanco A; Graña B; Durán M; Velasco E; Chirivella I; Cardeñosa EE; Tejada MI; Beristain E; Miramar MD; Calvo MT; Martínez E; Guillén C; Salazar R; San Román C; Antoniou AC; Urioste M; Benítez J
    Clin Cancer Res; 2008 May; 14(9):2861-9. PubMed ID: 18451254
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Icelandic founder mutation BRCA2 999del5: analysis of expression.
    Mikaelsdottir EK; Valgeirsdottir S; Eyfjord JE; Rafnar T
    Breast Cancer Res; 2004; 6(4):R284-90. PubMed ID: 15217494
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Association between the BRCA2 N372H variant and male breast cancer risk: a population-based case-control study in Tuscany, Central Italy.
    Palli D; Falchetti M; Masala G; Lupi R; Sera F; Saieva C; D'Amico C; Ceroti M; Rizzolo P; Caligo MA; Zanna I; Ottini L
    BMC Cancer; 2007 Sep; 7():170. PubMed ID: 17767707
    [TBL] [Abstract][Full Text] [Related]  

  • 26. After radical retropubic prostatectomy 'insignificant' prostate cancer has a risk of progression similar to low-risk 'significant' cancer.
    Sengupta S; Blute ML; Bagniewski SM; Inman B; Leibovich BC; Slezak JM; Myers RP; Zincke H
    BJU Int; 2008 Jan; 101(2):170-4. PubMed ID: 18173824
    [TBL] [Abstract][Full Text] [Related]  

  • 27. BRCA2 mutation in a family with hereditary prostate cancer.
    Grönberg H; Ahman AK; Emanuelsson M; Bergh A; Damber JE; Borg A
    Genes Chromosomes Cancer; 2001 Mar; 30(3):299-301. PubMed ID: 11170288
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety and efficacy of the specific endothelin-A receptor antagonist ZD4054 in patients with hormone-resistant prostate cancer and bone metastases who were pain free or mildly symptomatic: a double-blind, placebo-controlled, randomised, phase 2 trial.
    James ND; Caty A; Borre M; Zonnenberg BA; Beuzeboc P; Morris T; Phung D; Dawson NA
    Eur Urol; 2009 May; 55(5):1112-23. PubMed ID: 19042080
    [TBL] [Abstract][Full Text] [Related]  

  • 29. BRCA2 mutation in Icelandic prostate cancer patients.
    Sigurdsson S; Thorlacius S; Tomasson J; Tryggvadottir L; Benediktsdottir K; Eyfjörd JE; Jonsson E
    J Mol Med (Berl); 1997 Oct; 75(10):758-61. PubMed ID: 9383000
    [TBL] [Abstract][Full Text] [Related]  

  • 30. BRCA2 mutations in 154 finnish male breast cancer patients.
    Syrjäkoski K; Kuukasjärvi T; Waltering K; Haraldsson K; Auvinen A; Borg A; Kainu T; Kallioniemi OP; Koivisto PA
    Neoplasia; 2004; 6(5):541-5. PubMed ID: 15548363
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Promoter methylation in APC, RUNX3, and GSTP1 and mortality in prostate cancer patients.
    Richiardi L; Fiano V; Vizzini L; De Marco L; Delsedime L; Akre O; Tos AG; Merletti F
    J Clin Oncol; 2009 Jul; 27(19):3161-8. PubMed ID: 19470943
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The prevalence of BRCA1 and BRCA2 germline mutations in high-risk breast cancer patients of Chinese Han nationality: two recurrent mutations were identified.
    Li WF; Hu Z; Rao NY; Song CG; Zhang B; Cao MZ; Su FX; Wang YS; He PQ; Di GH; Shen KW; Wu J; Lu JS; Luo JM; Liu XY; Zhou J; Wang L; Zhao L; Liu YB; Yuan WT; Yang L; Shen ZZ; Huang W; Shao ZM
    Breast Cancer Res Treat; 2008 Jul; 110(1):99-109. PubMed ID: 17851763
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Germ-line alterations in MSR1 gene and prostate cancer risk.
    Seppälä EH; Ikonen T; Autio V; Rökman A; Mononen N; Matikainen MP; Tammela TL; Schleutker J
    Clin Cancer Res; 2003 Nov; 9(14):5252-6. PubMed ID: 14614006
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prostate-specific antigen velocity and the detection of gleason score 7 to 10 prostate cancer.
    Punglia RS; Cullen J; McLeod DG; Chen Y; D'Amico AV
    Cancer; 2007 Nov; 110(9):1973-8. PubMed ID: 17886252
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Patient-derived xenografts reveal that intraductal carcinoma of the prostate is a prominent pathology in BRCA2 mutation carriers with prostate cancer and correlates with poor prognosis.
    Risbridger GP; Taylor RA; Clouston D; Sliwinski A; Thorne H; Hunter S; Li J; Mitchell G; Murphy D; Frydenberg M; Pook D; Pedersen J; Toivanen R; Wang H; Papargiris M; Lawrence MG; Bolton DM
    Eur Urol; 2015 Mar; 67(3):496-503. PubMed ID: 25154392
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality.
    Tsai HK; D'Amico AV; Sadetsky N; Chen MH; Carroll PR
    J Natl Cancer Inst; 2007 Oct; 99(20):1516-24. PubMed ID: 17925537
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hereditary prostate cancer: clinical characteristics and survival.
    Bratt O; Damber JE; Emanuelsson M; Grönberg H
    J Urol; 2002 Jun; 167(6):2423-6. PubMed ID: 11992050
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cigarette smoking and prostate cancer-specific mortality following diagnosis in middle-aged men.
    Gong Z; Agalliu I; Lin DW; Stanford JL; Kristal AR
    Cancer Causes Control; 2008 Feb; 19(1):25-31. PubMed ID: 17906959
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Macrophage scavenger receptor 1 999C>T (R293X) mutation and risk of prostate cancer.
    Hope Q; Bullock S; Evans C; Meitz J; Hamel N; Edwards SM; Severi G; Dearnaley D; Jhavar S; Southgate C; Falconer A; Dowe A; Muir K; Houlston RS; Engert JC; Roquis D; Sinnett D; Simard J; Heimdal K; Møller P; Maehle L; Badzioch M; Eeles RA; Easton DF; English DR; Southey MC; Hopper JL; Foulkes WD; Giles GG;
    Cancer Epidemiol Biomarkers Prev; 2005 Feb; 14(2):397-402. PubMed ID: 15734964
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of socioeconomic status on prostate cancer diagnosis, treatment, and prognosis.
    Rapiti E; Fioretta G; Schaffar R; Neyroud-Caspar I; Verkooijen HM; Schmidlin F; Miralbell R; Zanetti R; Bouchardy C
    Cancer; 2009 Dec; 115(23):5556-65. PubMed ID: 19787636
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.